PARIS, April 18 /PRNewswire/ -- ExonHit Therapeutics, a drug and diagnostic discovery company, announced today that a number of its SpliceArray products are now available on the Affymetrix microarray platform. Today's announcement follows the supply and provider agreement between ExonHit and Affymetrix signed last October.
ExonHit's SpliceArrays that are now available on the Affymetrix GeneChip(R) platform include ExonHit's SpliceArrays for GPCR, Ion Channel, nuclear receptors and apoptosis pathways. Custom arrays are also available.
SpliceArrays are a new generation of microarrays that resolve the expression of genes at the level of their alternatively spliced transcripts. Recent publications suggest that over 80% of all human genes undergo alternative splicing, potentially producing many gene products with different functions from a single locus. With the perceived importance of alternative splicing at an all time high, the need for robust and accurate tools specifically designed to fully interrogate the complete transcriptome is critical for a clearer understanding of the onset of diseases and regulation of biological processes. ExonHit's proprietary SpliceArray content and patented probe configuration achieve this goal.
"This move is a step towards our goal of offering our SpliceArray technology to the marketplace on several platforms, thus providing maximum flexibility to our customers. Our SpliceArray products are now available on both Agilent and Affymetrix microarray platforms, the two main platforms used routinely in the fields of on-going research, drug discovery and diagnostics," said Bruno Tocque, President of ExonHit's Management Board.
For further information about SpliceArray, please visit www.splicearray.com, or email us at splicearray@exonhit.com .
About ExonHit Therapeutics
ExonHit Therapeutic is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.
ExonHit has a multi component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, "SpliceArrays" that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast and other major cancers.
In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit.
Founded in 1997, ExonHit is headquartered in Paris , France and has a US facility in Gaithersburg , Maryland . The Company is listed on Alternext of Euronext Paris .
The elements included in this communication may contain looking forward statements subject to certain risks and uncertainties. Actual results of the Company may differ materially from those indicated in the forward-looking statements because of different risk factors described in the Company Document de Base.
ExonHit Therapeutics SACONTACT: Contacts: ExonHit Therapeutics: Bruno Tocque, Chairman of theManagement Board, Tel: +33-1-58-05-47-00. Philippe Rousseau, ChiefFinancial Officer, philippe.rousseau@exonhit.com. Press relations: Tel :+44-(0)207-638-9571. Valerie Auffray / David Dible, Citigate Dewe Rogerson,valerie.auffray@citigatedr.co.uk
